Life sciences CVs are dense with acronyms that a general reviewer cannot rank. GMP, GCP, GLP, GDP and GVP describe different regulated activities with different competence requirements, and a candidate who has worked to one has not thereby worked to another. Add regulatory affairs, quality assurance and clinical operations as overlapping but distinct disciplines, and a sift that treats "GxP experience" as a single credential will produce a shortlist that does not survive the hiring manager.
The fix is to force the ambiguity open: which practice, in what role, under whose inspection.
Separating the GxP Family
These are not interchangeable and the differences matter operationally.
Good Manufacturing Practice
Governs the manufacture of medicines. Relevant to production, quality control, qualified persons and validation roles. Experience here is about batch records, deviations, change control, qualification and validation, and inspection readiness.
Good Clinical Practice
Governs clinical trials involving human participants. Relevant to clinical operations, monitoring, data management and pharmacovigilance-adjacent roles. Experience is about protocol compliance, informed consent processes, source data verification and site management.
Good Laboratory Practice
Governs non-clinical safety studies. A narrower population and frequently confused with general laboratory experience, which is not the same thing at all.
Good Distribution Practice
Governs the wholesale distribution of medicines. Relevant to supply chain, warehousing and responsible person roles.
Good Pharmacovigilance Practice
Governs safety monitoring of authorised products. Relevant to drug safety, case processing, signal detection and QPPV-adjacent roles.
A candidate whose entire career has been in GCP monitoring is not a GMP candidate. Both are genuinely regulated experience, and treating the acronyms as a single pool wastes everybody's time.
What to Establish, in Order
- Which practice, explicitly. Require it as a structured field rather than inferring it from prose. Multiple selections allowed, because some careers genuinely span more than one.
- The role within it. Executing a process, reviewing and approving, or owning the system. These are three different seniority levels and CVs blur them constantly.
- Inspection exposure. Whether the candidate has been present during a regulatory inspection, and in what capacity. Having been inspected changes how somebody works, and it is the strongest single signal in this sector.
- Product type and phase. Small molecule, biologic, advanced therapy, device or combination product, and for clinical roles the trial phases worked on.
- Systems by name. Quality management, document management, clinical data and safety database platforms. Named systems indicate hands-on use; categories indicate exposure.
Regulatory Affairs Needs Its Own Rubric
Regulatory affairs is frequently sifted as though it were quality assurance, and the requirements are different.
What matters is submission experience: which procedures the candidate has worked on, whether they authored or reviewed, which territories, and whether they have handled agency questions during assessment. Authoring a module is a different capability from coordinating a submission, and coordinating one is different again from owning the regulatory strategy for a product.
Territory matters more than candidates realise. UK and EU procedures diverged following the transition period, and experience of one does not automatically transfer. A sift should capture territories explicitly rather than accepting "European regulatory experience".
Qualified Persons and Named Roles
Some roles in this sector are legally named individuals rather than job titles, and screening for them is binary.
A Qualified Person for batch certification must meet defined eligibility criteria. A Responsible Person for wholesale distribution is a named role under a licence. A Qualified Person for Pharmacovigilance is similarly defined. Where a vacancy requires one of these, eligibility is a factual threshold and not a matter of comparable experience.
Capture eligibility as a yes or no field with the basis stated, and verify rather than infer. A candidate who has deputised for a QP is not a QP.
Where the Sift Loses Good Candidates
Treating academic research as laboratory experience. A postdoctoral researcher has genuine scientific capability and frequently no experience of working inside a regulated quality system. That is a training gap rather than a disqualification, and screening them out entirely narrows a pool that is already tight in a sector where 57 per cent of UK employers reported skills shortages in 2026.
Requiring the same product type. Frequently a proxy for regulated discipline, which transfers well. Assess the discipline directly.
Overweighting contract research organisation versus sponsor experience. Both produce real GCP capability, and the distinction is usually about breadth versus depth rather than quality.
Rejecting overseas qualifications on origin. Not defensible under the Equality Act 2010. Where UK or EU territory knowledge is genuinely required, assess the knowledge directly.
Screening at Volume in This Sector
Life sciences roles are high value and the applicant pools are moderate rather than enormous, which changes the economics. The cost of a sift here is not reading time. It is the cost of interviewing candidates who lack a threshold requirement, and of missing candidates whose relevant experience was described in unfamiliar language.
Structured fields solve the first problem: practice, role level, inspection exposure, territories, named eligibility. Those filter objectively and cost nothing to assess.
Evidence-based assessment solves the second. For each requirement, record whether it is evidenced with specifics, claimed without detail, or absent. A candidate who describes managing a deviation investigation from observation to CAPA closure has evidenced quality capability regardless of whether they used the phrase your advert used.
Frequently Asked Questions
Is GxP Experience Transferable Between Practices?
The discipline of working inside an inspected quality system transfers well. The specific regulatory content does not. Assess both separately rather than treating them as one.
How Important Is Inspection Experience?
It is the strongest available signal for quality and regulatory roles, and worth capturing as a discrete field. Being inspected teaches what documentation actually has to withstand.
Should We Require a Life Sciences Degree?
For scientific and QP-track roles, usually yes and often as a regulatory requirement. For quality systems, documentation and project roles it frequently functions as a proxy and narrows the pool without evidencing capability.
How Do We Handle Candidates From Academia?
Assess scientific capability and treat regulated-environment experience as a separate, trainable requirement. Say so in the advert if you are open to it, because otherwise they will not apply.
Does the EU AI Act Affect Our Screening?
Recruitment AI is high-risk under Annex III. The substantive obligations for standalone Annex III systems now apply from 2 December 2027 following the Digital Omnibus amendment, with transparency obligations from 2 December 2026. If you recruit for EU-located roles or have EU entities, that timetable applies to you.
The Position
Require the practice, the role level within it, inspection exposure, product type and territories as structured fields. Treat named regulatory roles as binary eligibility and verify them. Give regulatory affairs its own rubric built around submission experience and territory. Assess the discipline of working under inspection separately from specific regulatory content. And keep the door open to academic candidates where the gap is trainable.
The acronyms are the whole problem. Make candidates disambiguate them rather than guessing.
This article is general guidance, not regulatory advice. Consult current MHRA and EMA requirements and take specialist advice on named role eligibility.
Sources
Medicines and Healthcare products Regulatory Agency. Good Clinical Practice for Clinical Trials.
https://www.gov.uk/guidance/good-clinical-practice-for-clinical-trials
The Stationery Office. Equality Act 2010.
https://www.legislation.gov.uk/ukpga/2010/15/contents
GOV.UK. Equality Act 2010: Guidance.
https://www.gov.uk/guidance/equality-act-2010-guidance
EU Artificial Intelligence Act. Annex III: High-Risk AI Systems Referred to in Article 6(2).
https://artificialintelligenceact.eu/annex/3/
Information Commissioner's Office. Employment Practices: Recruitment and Selection.
https://ico.org.uk/for-organisations/uk-gdpr-guidance-and-resources/employment/recruitment-and-selection/
InsightCircle



